What is RiconPharma?
RiconPharma is a dedicated research and development company established in April 2008. Operating from a state-of-the-art 10,000 sq. ft. R&D facility in Denville, NJ, USA, the company specializes in the innovation of novel drug delivery systems. Its core competencies include developing alternate routes of administration, enhancing existing products, and creating modified-release dosage forms. RiconPharma's work supports both the creation of new pharmaceutical products and the lifecycle management of approved medications, positioning it as a key player in pharmaceutical innovation and product enhancement.
How much funding has RiconPharma raised?
RiconPharma has raised a total of $2M across 2 funding rounds:
Debt
$1M
Debt
$1M
Debt (2020): $1M with participation from PPP
Debt (2021): $998K led by PPP
What's next for RiconPharma?
The substantial enterprise-level capital and recent strategic investment signal RiconPharma's advanced stage in its growth trajectory. This infusion of funds is likely earmarked for accelerating the development and commercialization of its novel drug delivery systems, expanding its R&D capabilities, and potentially forging strategic partnerships within the pharmaceutical industry. The company's focus on both new product development and lifecycle management suggests a dual strategy aimed at sustained market presence and revenue generation. Future endeavors will likely concentrate on clinical validation, regulatory approvals, and market penetration for its innovative pharmaceutical solutions.
See full RiconPharma company page
